CFO of Nurix Therapeutics Sells Shares Valued at $55,798

Houte Hans Van, the Chief Financial Officer (CFO) of Nurix Therapeutics, Inc. (NASDAQ:NRIX), recently sold 2,811 shares of the company's stock in a transaction that took place on Thursday, January 30th. The shares were sold at an average price of $19.85, which brought the total value of the transaction to $55,798.35.

After this sale, Houte Hans Van now holds 39,549 shares of Nurix Therapeutics, with an estimated value of approximately $785,047.65. This transaction marks a 6.64% reduction in Van's ownership of the stock. The details of the sale were officially disclosed in a filing with the Securities and Exchange Commission (SEC), which interested parties can access for further information.

In addition to the recent sale, Houte Hans Van also engaged in previous transactions. On November 1st, he sold 3,546 shares of Nurix Therapeutics at an average price of $24.28, resulting in a total value of $86,096.88.

Stock Performance of Nurix Therapeutics

The stock of Nurix Therapeutics opened at $20.01 on Friday. The company has experienced a 1-year low of $7.79 and a 1-year high of $29.56. Additionally, the 50-day moving average price is currently $20.14, while the 200-day moving average price stands at $22.40.

On January 28th, Nurix Therapeutics reported its quarterly earnings results, showing an earnings per share (EPS) of ($0.75), which fell short of the consensus estimate of ($0.67) by $0.08. The company has recorded a negative return on equity of 63.38% and a negative net margin of 354.85%. Analysts predict that Nurix Therapeutics will post an EPS of -2.73 for the ongoing year.

Analyst Ratings and Predictions

Recent research reports have put Nurix Therapeutics under the spotlight in Wall Street discussions. Jefferies Financial Group initiated coverage with a "buy" rating, setting a price target of $41.00, while UBS Group also started coverage, giving it a "buy" rating with a $35.00 price target. Meanwhile, JPMorgan Chase lowered its price target from $31.00 to $30.00 but maintained an "overweight" rating. Stephens reaffirmed an "overweight" rating with a $31.00 target price, and BMO Capital Markets began coverage with an "outperform" rating and a $35.00 price objective. Presently, one analyst has rated Nurix Therapeutics as a hold, while 16 others have given it a buy rating. According to data from MarketBeat, the current consensus rating for Nurix Therapeutics is "Moderate Buy," with an average price target of $30.71.

Institutional Investor Activity

Institutional trading activity has been notable for shares of Nurix Therapeutics. In the third quarter, JPMorgan Chase & Co. increased its investments by 85.2%, now holding 68,148 shares valued at approximately $1.53 million. Barclays PLC boosted its position by 77.9%, owning 128,344 shares worth about $2.88 million. FMR LLC saw a dramatic increase in holdings by 675.9%, now possessing 586,902 shares valued at around $13.19 million. Dynamic Technology Lab Private Ltd acquired new shares, while Franklin Resources Inc. expanded its position in the stock by 52.4%, holding 123,101 shares valued at $2.77 million.

Overview of Nurix Therapeutics

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing small molecule and cell therapies aimed at treating various forms of cancer, inflammatory conditions, and other diseases. The company works on several promising products, including NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader targeting relapsed or refractory B-cell malignancies; NX-5948, which is similar in focus and treatment applications; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor intended for immuno-oncology indications.

CFO, Stock, Transaction